cloprostenol and Hypotrichosis

Topics: Amides; Bimatoprost; Cloprostenol; Drug-Related Side Effects and Adverse Reactions; Eyelashes; Humans; Hypotrichosis; Ophthalmic Solutions; Prostaglandins, Synthetic

The Food and Drug Administration has approved bimatoprost ophthalmic solution (0.03%) for the treatment of eyelash hypotrichosis. Previous reports of its efficacy in eyebrow hypotrichosis are anecdotal.. To assess the efficacy and safety of bimatoprost 0.03% ophthalmic solution applied to the eyebrows in a randomized, double-blind, vehicle-controlled study.. Subjects (n = 20) with mild to moderate eyebrow hypotrichosis enrolled in the study. One group (Bim) applied bimatoprost to each eyebrow daily for 9 months, and another applied vehicle nightly to each eyebrow for 5 months. Subjects in the latter group were re-randomized to apply bimatoprost (Veh-Bim Group) or vehicle (Veh Group) daily to each eyebrow for 4 months. The primary end point was investigator-assessed eyebrow appearance; secondary end points were subject-reported outcomes.. Investigator assessments showed significant improvements from baseline to 6 (p = .002) and 7 (p = .005) months for the eyebrows treated with bimatoprost. p-Values for the Veh-Bim and Veh groups were not significant at any time point. End-of-study subject satisfaction with eyebrow fullness or thickness and darkness or color was greater in the Bim group than in the Veh group. Adverse effects were not observed.. Bimatoprost 0.03% ophthalmic solution applied daily for 9 months improves the appearance of eyebrows noticeably more than vehicle, without side effects.

Topics: Amides; Bimatoprost; Cloprostenol; Cosmetic Techniques; Double-Blind Method; Eyebrows; Female; Humans; Hypotrichosis; Middle Aged; Ophthalmic Solutions; Patient Satisfaction; Pilot Projects

Hypotrichosis of the eyelashes may negatively influence an individual's self-perception and appearance. Assessing the impact of treatment from a patient's perspective may be particularly relevant in trials of aesthetic agents. Once-daily dermal (topically applied) administration of bimatoprost ophthalmic solution 0.03% has been associated with increased eyelash prominence (ie, length, thickness, darkness).. The authors assess patient-reported outcomes (PRO) after treatment with bimatoprost for hypotrichosis of the eyelashes.. In this multicenter, double-masked, randomized, vehicle-controlled, parallel clinical trial, 4 PRO questionnaires were distributed to 278 patients (bimatoprost [n = 137] and vehicle [n = 141]). The primary PRO questionnaire was the 23-item Eyelash Satisfaction Questionnaire (ESQ), which measured satisfaction in 3 domains: length, fullness, and overall satisfaction (LFOS); confidence, attractiveness, and professionalism (CAP); and impact on daily routine (DR).. By week 16, the bimatoprost group reported significantly greater improvements from baseline on all ESQ items (P ≤ .0433). These improvements were sustained through the 4-week posttreatment study visit. Patient satisfaction was significantly greater in the bimatoprost group than in the vehicle group for all 3 domains: LFOS (weeks 8-20; P ≤ .0052), CAP (weeks 12-20; P < .0001), and DR (weeks 16 and 20; P ≤ .01).. The bimatoprost group reported significantly greater levels of positive patient outcomes and satisfaction than the vehicle group across all 23 questions and all 3 domains of the primary PRO questionnaire. These results support the effectiveness, as measured by objective measures and PRO, of once-daily bimatoprost ophthalmic solution 0.03% at producing more prominent eyelashes in adults.

Topics: Administration, Topical; Adult; Aged; Amides; Bimatoprost; Body Image; Canada; Cloprostenol; Cost of Illness; Double-Blind Method; Eyelashes; Female; Humans; Hypotrichosis; Male; Middle Aged; Ophthalmic Solutions; Patient Satisfaction; Self Concept; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States; Young Adult

Few dermatologic conditions carry as much anxiety and emotional distress as hair loss resulting from a disease condition such as alopecia areata or as a result of cytotoxic drug treatment, e.g., after chemotherapy. Bimatoprost 0.03% solution is a Food and Drug Administration-approved prescription product indicated for the treatment of eyelash hypotrichosis. The product was investigated in a double-masked, randomized, and placebo-controlled study in patients who had significant eyelash loss or hypotrichosis as a result of chemotherapy. Once-daily treatment with bimatoprost ophthalmic solution 0.03% to the upper eyelid margin restored eyelash growth and prominence more quickly than the slower, natural course of recovery observed in the vehicle control subjects. The eyelash prominence measured using a validated Global Eyelash Assessment (GEA) scale demonstrated a statistically significant increase over placebo following 6 months of treatment. Efficacy was also demonstrated using a validated objective digital image analysis methodology to show significant increase in eyelash length, thickness/fullness, and darkness in these patients. Bimatoprost was found to be well tolerated over the 1-year treatment period.

Topics: Amides; Antineoplastic Agents; Bimatoprost; Cloprostenol; Dermatologic Agents; Double-Blind Method; Eyelashes; Humans; Hypotrichosis; Patient Satisfaction; Severity of Illness Index

Topics: Administration, Topical; Amides; Antihypertensive Agents; Bimatoprost; Cloprostenol; Eyelashes; Humans; Hypotrichosis

In December 2008, bimatoprost ophthalmic solution 0.03% was approved in the United States for the treatment of hypotrichosis of the eyelashes. Since then, there have been several reports in the literature on the off-label use of bimatoprost ophthalmic solution 0.03% for the treatment of thinning in other hair bearing areas, such as in the eyebrows and in the scalp. Herein, a prospective pilot study is presented in which bimatoprost ophthalmic solution 0.03% is evaluated for helping to re-grow hair in the eyebrow region of ten female patients.

Topics: Adult; Amides; Bimatoprost; Cloprostenol; Eyebrows; Eyelashes; Female; Humans; Hypotrichosis; Middle Aged; Ophthalmic Solutions; Patient Satisfaction; Pilot Projects; Prospective Studies

Topics: Administration, Topical; Amides; Antihypertensive Agents; Bimatoprost; Cloprostenol; Eyelashes; Humans; Hypotrichosis; Ophthalmic Solutions; Treatment Outcome

The efficacy and safety of bimatoprost ophthalmic solution 0.03% for treating hypotrichosis were shown in a randomized controlled trial and in an open-label study. To date, no data on real-world experience have been published.. To evaluate long-term patient satisfaction, usage patterns, and safety of bimatoprost 0.03% in clinical practice.. In this retrospective chart review with a cross-sectional design, adult patients exposed to bimatoprost 0.03% for at least 12 months were randomly sampled from 16 investigational sites. Charts were reviewed for medication usage characteristics and adverse events (AEs). At a study visit, questionnaires eliciting patient-reported outcomes were administered and spontaneously reported AEs were tabulated.. Analysis included 585 subjects with a mean (SD) treatment duration of 19.3 (4.3) months. Patient satisfaction with bimatoprost 0.03% was 92.5%; on average, approximately 3 applications per week maintained benefits. Overall, 27.4% of patients spontaneously recalled experiencing AEs while on treatment; however, patient charts showed that only 4 AEs were documented. No instances of iris hyperpigmentation occurred. No serious or severe AEs were noted.. Treatment with bimatoprost 0.03% for at least 12 months is safe, and long-term use is associated with a high degree of satisfaction.

Topics: Adult; Amides; Bimatoprost; Cloprostenol; Cross-Sectional Studies; Erythema; Eyelashes; Eyelid Diseases; Female; Humans; Hypotrichosis; Male; Middle Aged; Ophthalmic Solutions; Patient Satisfaction; Pigmentation Disorders; Pruritus; Retrospective Studies; Treatment Outcome

Topical bimatoprost was FDA approved in December of 2008 for the treatment of eyelash hypotrichosis. Since its approval, some physicians have advocated the use of bimatoprost "off label" for hair growth in other areas, such as the scalp or eyebrows, but there has yet to be published scientific evidence to support this use. We report one of the first cases of significant eyebrow hair growth in a patient after use of topical bimatoprost for eyebrow hypotrichosis.

Topics: Administration, Topical; Amides; Bimatoprost; Cloprostenol; Eyebrows; Female; Follow-Up Studies; Humans; Hypotrichosis; Middle Aged; Treatment Outcome

Topics: Amides; Bimatoprost; Cloprostenol; Cosmetics; Drug Industry; Eyelashes; Glaucoma, Open-Angle; Humans; Hypotrichosis

Topics: Adult; Amides; Antihypertensive Agents; Bimatoprost; Cloprostenol; Eyelashes; Eyelid Diseases; Female; Humans; Hyperpigmentation; Hypotrichosis; Middle Aged; Ophthalmic Solutions; Skin Pigmentation

Topics: Administration, Topical; Amides; Bimatoprost; Cloprostenol; Drug Costs; Eyelashes; Humans; Hypotrichosis; Pharmaceutical Solutions; Treatment Outcome

Topics: Amides; Bimatoprost; Cloprostenol; Drug Costs; Eye Color; Humans; Hypotrichosis; Keratitis; Pigmentation Disorders; Prostaglandins, Synthetic